{
    "id": 29085,
    "fullName": "CUX1 - ALK",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CUX1-ALK results from the fusion of CUX1 and ALK, demonstrating transformation in cell culture and constitutive phosphorylation activity (PMID: 30010043). CUX1-FGFR1 fusions have been identified in non-small cell lung cancer (PMID: 30010043).",
            "references": [
                {
                    "id": 13170,
                    "pubMedId": 30010043,
                    "title": "CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30010043"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1523,
        "geneSymbol": "CUX1",
        "terms": [
            "CUX1",
            "CASP",
            "CDP",
            "CDP/Cut",
            "CDP1",
            "Clox",
            "COY1",
            "CUTL1",
            "CUX",
            "Cux/CDP",
            "GDDI",
            "GOLIM6",
            "Nbla10317",
            "p100",
            "p110",
            "p200",
            "p75"
        ]
    },
    "variant": "CUX1 - ALK",
    "createDate": "12/09/2018",
    "updateDate": "10/31/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15415,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Xalkori (crizotinib) treatment of a non-small cell lung cancer patient harboring a CUX1-ALK fusion, resulted in progression-free survival of 20 months (PMID: 30010043).",
            "molecularProfile": {
                "id": 31014,
                "profileName": "CUX1 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13170,
                    "pubMedId": 30010043,
                    "title": "CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30010043"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31014,
            "profileName": "CUX1 - ALK",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}